Veradermics (MANE) Increases IPO Size and Sets Price at $17, Exceeding Expected Range by $1

Veradermics, a promising biotech company, recently made waves by upsizing its IPO, offering 15.08 million shares instead of the originally planned 13.35 million in its prospectus. Priced at $17.00 per share, exceeding its price range by $1.00, the company successfully raised $256.36 million on the night of February 3, 2026. The stock is scheduled to debut on the New York Stock Exchange the following day.

With this pricing, Veradermics boasted a market capitalization of $596.32 million, a significant figure in the biotech sector. Notable financial institutions, such as Jefferies, Leerink Partners, Citigroup, and Cantor, played crucial roles as joint book-runners in this IPO, underscoring the industry’s confidence in the company’s potential.

Specializing in Phase 2 and Phase 3 biotechnology, Veradermics focuses on developing an extended-release formulation of minoxidil, a common blood pressure medication, to address pattern hair loss in both men and women. This innovative approach to combatting hair loss, a pervasive issue, makes Veradermics’ product unique and highly anticipated in the market.

In a significant development, Eli Lilly & Company expressed interest in acquiring 4.9% of Veradermics’ stock through the IPO, as indicated in a recent SEC filing. Additionally, Wellington Management, a cornerstone investor, signaled interest in purchasing up to $30 million worth of stock, potentially acquiring 15% of the IPO shares. These investments underscore the confidence major players in the industry have in Veradermics’ future prospects.

Based in New Haven, Connecticut, Veradermics is currently conducting clinical trials for its leading drug candidate, VDPHL01. These trials focus on male and female patients with mild to moderate pattern hair loss, showcasing the company’s commitment to addressing a widespread issue in a comprehensive manner. The proceeds from the IPO are earmarked for funding these vital clinical trials, highlighting Veradermics’ dedication to advancing their research and development efforts.

Despite its promising potential, Veradermics reported a net loss of $53.81 million for the 12 months ending September 30, 2025. This financial information underscores the company’s current position in a competitive market and its ongoing investments in research and development to drive future growth and success.

As Veradermics prepares to debut on the stock exchange, industry experts and investors are closely watching its progress. The buzz surrounding this IPO reflects the market’s anticipation of Veradermics’ innovative approach to addressing pattern hair loss and its potential to make a significant impact in the biotechnology sector.